Skip to main content

Table 4 Clinical and therapeutic characteristics

From: Prospective comparative multi-centre study on imported Plasmodium ovale wallikeri and Plasmodium ovale curtisi infections

  P ovale curtisi
(n=35)
P ovale wallikeri
(n=44)
p
Asymptomatic 2 (5.7) 2 (4.5) 1
Fever 32 (91.4) 39 (88.6) 1
Headache 17 (48.6) 29 (65.9) 0.121
Nausea 9 (25.7) 11 (25.0) 0.942
Arthralgia 10 (28.6) 15 (34.1) 0.600
Myalgia 17 (48.6) 18 (40.9) 0.496
Vomitus 4 (11.4) 12 (26.3) 0.082
Abdominal pain 5 (14.3) 3 (6.8) 0.460
Diarrhea 4 (11.4) 5 (11.4) 1
Other (cough, dyspnea, chest pain, dizziness) 9 (25.7) 10 (22.7) 0.758
Duration of hospitalization, median days (IQR) 4 (2.0–6.0) 3 (3.0–6.0) 0.713
Treatment    0.826
 Chloroquine 17 (48.6) 18 (40.9)  
 Atovaquone/proguanil 12 (34.2) 11 (25.0)  
 Quinine + doxycycline   2 (4.5)  
 Atovaquone/proguanil + chloroquine 1 (2.9) 1 (2.3)  
 Artesunate + artemether–lumefantrine 1 (2.9)   
 Dihidroartemisinin–piperaquine 3 (8.6) 7 (15.9)  
 Artemether–lumefantrine   1 (2.3)  
 Artesunate + chloroquine   1 (2.3)  
 Artesunate + atovaquone/proguanil 1 (2.9)   
 Artesunate   1 (2.3)  
 Lost to follow up, no treatment   2 (4.5)  
Primaquine 25 (71.4) 34 (81.0) 0.325
Severe malaria and complications    1
 Total bilirubin > 3 mg/dL and haemoglobin < 7 g/dL 1 (2.9)a   
 Total bilirubin > 3 mg/dL   3 (6.8)b  
 Haemoglobin < 7 g/dL 1 (2.9)   
 Haemophagocytosis   1 (2.3)  
Exitus 0 0 1
  1. Values are no. (%) or no. positive/total no. (%) and median (interquartile range)
  2. IQR interquartile range
  3. aThis patient had drepanocytosis
  4. bOne patient had drepanocytosis and G6PDH deficit and other patient had diabetes